| Stage | CRH | % of rev | EXP | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $11.4B | 100.00% | $479M | 100.00% | CRH ×23.79 |
| Gross profit | $4.4B | 38.79% | $106M | 22.19% | CRH +16.6pp |
| Operating income | $1.9B | 16.64% | $83M | 17.38% | EXP +0.7pp |
| Pre-tax income | $1.7B | 15.08% | $78M | 16.36% | EXP +1.3pp |
| Net income | $1.2B | 10.39% | $60M | 12.56% | EXP +2.2pp |
| Stage | CRH | EXP | Gap · A − B |
|---|---|---|---|
| Revenue | $11.4B100.00% | $479M100.00% | CRH ×23.79 |
| Gross profit | 38.79%$4.4B | 22.19%$106M | CRH +16.6pp |
| Operating income | 16.64%$1.9B | 17.38%$83M | EXP +0.7pp |
| Pre-tax income | 15.08%$1.7B | 16.36%$78M | EXP +1.3pp |
| Net income |
| 10.39%$1.2B |
| 12.56%$60M |
| EXP +2.2pp |
None
No disclosed counterparties: CRH.